HHS & Healthcare Contracts Intelligence — October 09, 2026

The firm-fixed-price contract carries a $83,713,826 base-plus-options value with $17,555,624 outlayed to date and runs to 2029-11-15. Funding supports clinical validation for a future FDA application, so commercial upside depends on regulatory outcome not yet secured.

Only about 24% of the $191,938,367 base-plus-options ceiling is obligated, and roughly 45% of the current obligation has been outlayed through the 2027-12-31 end date. The recipient's revenue base and parent's listing status are not established, limiting assessment of financial materiality.

Successful completion of the clinical training and validation studies under the $65.5M award would support an FDA submission for an expanded TBI test indication. FDA decision timing is not stated in the data.

Basilea's contract shows high pricing risk, with only about 24% of the $191.9M ceiling obligated and about 45% of the $45.2M current obligation outlayed by the 2027-12-31 end date, leaving significant funded work and option dependence ahead.

Both awards depend on continued HHS/ASPR BARDA appropriations; the data does not establish a multi-year budget trend, so funding continuity beyond current obligations is uncertain.

Abbott's commercial benefit depends on a future FDA marketing application for an expanded TBI indication, and no approval or decision timeline is stated.

Abbott's TBI diagnostic franchise could expand to pediatric and adult traumatic brain injury testing if the BARDA-funded validation supports the expanded FDA indication.

Basilea's antibiotic development for drug-resistant gram-negative bacteria could generate value if options are exercised toward the $191.9M ceiling and development advances.

Both awards originate from HHS/ASPR's BARDA and fund diagnostic validation and therapeutic development, combining for $110.7M in obligations. Evidence covers two awards only, so the data does not establish a broader multi-year spending trend.

{"entity" => "Abbott Laboratories", "reason" => "$65,469,510 BARDA obligation with $17,555,624 outlayed; the expanded TBI indication depends on a future FDA marketing application.", "trigger" => "Option exercise or obligation increase toward $83,713,826, and FDA submission or decision on the expanded TBI indication"}

{"entity" => "Basilea Pharmaceutica International Ltd / Basilea Pharmaceutica AG", "reason" => "$45,192,122 current obligation against a $191,938,367 ceiling, with about 45% outlayed and high pricing risk.", "trigger" => "Option exercise toward the ceiling, outlay progression before 2027-12-31, and any extension to 2029-12-31"}